The effect of benzoyl peroxide 9.8% emollient foam on reduction of Propionibacterium acnes on the back using a short contact therapy approach

Benzoyl peroxide (BP) exerts its therapeutic effect for acne vulgaris through reduction of Propionibacterium acnes. A 1.0 to 2.0 log reduction in P acnes has been demonstrated primarily on the face with use of "leave-on" BP formulations, but also with some BP cleansers. In addition to use for facial acne vulgaris, cleanser formulations of BP are commonly used for truncal acne vulgaris due to ease of use on a large body-surface area and to avoid bleaching of fabric. To date, evaluation of P acnes reduction on the trunk has not been well studied with BP formulations, especially with the use of recognized and standardized methods to accurately determine P acnes colony counts. A previous study demonstrated that a BP 8% cleanser did not reduce counts of P acnes on the back when subjects were instructed to apply the cleanser in the shower, allow it to dry for 20 seconds on the skin, and then rinse off the cleanser. Evaluation of specified time intervals between application on the back and rinsing with BP formulations would help to better define the necessary skin contact time associated with high reductions of P acnes (>90%), recognizing also the potential roles of BP concentration and vehicle. This 2 week study using quantitative bacteriologic cultures evaluates the effectiveness of BP 9.8% emollient foam in reducing P acnes levels on the back with 2 minutes of skin contact time and compares results with a BP 5.3% "leave-on" emollient foam formulation. Short contact therapy utilizing a 2 minute skin contact time with BP 9.8% emollient foam used once daily over a 2 week duration was highly effective in reducing the quantity of P acnes organisms on the back and provided comparable colony count reduction to "leave on" therapy using BP 5.3% emollient foam.     

A closer look at truncal acne vulgaris: prevalence, severity, and clinical significance

Data is very limited on the demographics, epidemiology, grading, and management of truncal acne vulgaris. In this study completed in 5 cities across the US, 696 patients were assessed to evaluate the frequency and severity of truncal acne vulgaris. Approximately 50% of patients who presented with acne vulgaris demonstrated involvement on the chest and/or back, with more than 3% presenting with truncal acne lesions alone. Interestingly, approximately 1 out of 4 patients who presented with both facial and truncal acne involvement did not voluntarily mention the presence of truncal acne as part of their presenting complaint. In such cases, the presence of truncal acne lesions was detected by clinical examination. A grading system for truncal acne vulgaris is also presented. The majority of patients presenting with truncal acne vulgaris exhibited mild to moderate severity and more than 75% were interested in treatment for truncal acne lesions.     

盐酸克林霉素凝胶治疗寻常性痤疮的临床研究

目的:评价盐酸克林霉素凝胶在治疗寻常性痤疮中的疗效和安全性.方法:寻常性痤疮患者200例,采用严格的多中心、双盲、随机平行对照试验的方法.治疗组100例应用1%盐酸克林霉素凝胶治疗,对照组100例应用1%克林霉素磷酸酯凝胶治疗,比较两组疗效.结果:治疗组有效率为84.0%,对照组为78.0%,经Ridit检验,两组疗效差异不显著;两组的不良反应均较轻.结论:1%盐酸克林霉素凝胶治疗寻常性痤疮是安全、有效的.     

Solubilized benzoyl peroxide versus benzoyl peroxide/clindamycin in the treatment of moderate acne

BACKGROUND: Benzoyl peroxide (BPO) is poorly soluble. A solubilized formulation of BPO has been developed to maximize its bioavailability and enhance follicular penetration. METHODS: Patients with acne vulgaris were randomly assigned to receive solubilized BPO 5% gel on one side of the face and a BPO 5%/clindamycin 1% combination product on the contralateral side, twice daily for 4 weeks. RESULTS: Of 23 patients enrolled, 100% completed the study. Reductions in lesion count with the solubilized BPO gel were at least as great as with BPO/clindamycin--and significantly greater (P< or =.05) for noninflammatory lesions at week 1 and inflammatory lesions at week 4. Both regimens were generally well tolerated and patient satisfaction was comparable. CONCLUSIONS: Solubilized BPO 5% gel monotherapy offers significantly greater efficacy, and comparable patient satisfaction, compared with BPO/clindamycin. The early reduction in lesion counts observed with the solubilized BPO gel in the absence of an antibiotic is clinically relevant.     

复方克林霉素搽剂治疗寻常痤疮

目的 :观察复方克林霉素搽剂治疗寻常痤疮的疗效。方法 :采用开放、多中心临床试验方法以复方克林霉素搽剂治疗 153例寻常痤疮病人 (男性53例 ,女性 10 0例 ,年龄 2 2a±s 6a) ,每日 3次涂于面部 ,连续 4wk ,每 2wk随访。结果 :复方克林霉素搽剂治疗寻常痤疮 ,4wk总显效率达 83.0 % ,对脓疱和丘疹的总有效率分别为 96.1%和 80 .7% ,不良反应率为 1.9%。结论 :复方克林霉素搽剂治疗痤疮疗效显著 ,安全性高 ,使用方便     

一清胶囊联合复方氯霉素洗剂治疗寻常型座疮的疗效观察

目的观察一清胶囊联合复方氯霉素洗剂治疗寻常型痤疮的临床疗效。方法选择门诊寻常型座疮患者96例,随机分为两组。治疗组患者口服一清胶囊每次2g,3次/d,复方氯霉素洗剂外用患处,2次/d。对照组患者口服盐酸四环素片每次0.25g,4次/d,2周后改为每次0.25g,2次/d,复方氯霉素洗剂外用患处,2次/d。两组疗程均为1个月。结果治疗组和对照组治疗后1个月的总有效率分别为91.67%和77.08%,两组比较差异有统计学意义(χ2=3.87,P<0.05)。结论一清胶囊联合复方氯霉素洗剂治疗寻常型座疮是安全有效的,值得临床推广使用。     

Doxycycline plus levamisole: combination treatment for severe nodulocystic acne

BACKGROUND: Levamisole is an agent without much potential use alone, but through immunomodulation, may synergistically improve the efficacy of other drugs like doxycycline in the treatment of acne vulgaris. OBJECTIVE: The goal of this study was to determine the efficacy of levamisole in addition to doxycycline in the treatment of patients suffering from severe nodulocystic acne. METHODS: A double-blind, randomized, placebo-controlled trial was conducted in the dermatology clinic of Rasoul-e-Akram Hospital in Tehran, Iran in 2006. Sixty patients were randomly assigned to 1 of 2 study groups. The case group was administered oral levamisole 2.5 mg/kg/wk (up to 150 mg/wk) plus doxycycline 100 mg daily and the control group was given 100 mg of oral doxycycline daily and a placebo. Patients were evaluated at baseline, and at 2-month, 4-month, and 6-month checkpoints. RESULTS: The responses to treatment were significantly higher in the case group according to the reduction in total lesions count, acne severity index; and papule/pustule and nodule/cyst count at the 2nd, 3rd, and 4th visits. CONCLUSION: Results indicated that adding oral levamisole to doxycycline is an effective treatment for severe nonresponsiveness to conventional treatments of acne vulgaris. In the patient group, levamisole was well tolerated with an acceptable safety profile. At the time of publication, this study is the first clinical trial that suggests levamisole as an effective new treatment for severe acne vulgaris.     

The safety and efficacy of clindamycin phosphate foam 1% versus clindamycin phosphate topical gel 1% for the treatment of acne vulgaris

Clindamycin phosphate is the most widely used topical antibacterial agent for acne treatment. Treatment of patients with mild to moderate acne vulgaris with a new foam formulation (clindamycin foam, CF) for 12 weeks was at least as effective as clindamycin gel (CG) based on the Investigator's Static Global Assessment (ISGA) score. CF was superior to CG based on the reduction from baseline in total (P = .0014), inflammatory (P = .0478), and noninflammatory (P = .0037) acne lesion counts. Additionally, CF achieved efficacy that was superior to that of vehicle foam based on ISGA score (P = .0025) and all 3 lesion counts (all P < .05). Adverse experiences in the active treatment groups were mild or moderate and transient in nature. Thus the foam formulation of clindamycin is a safe and effective acne treatment; the unique foam delivery vehicle may offer cosmetic benefits to the patient and thus increase compliance.     

β胡萝卜素联合克林霉素治疗寻常痤疮的临床观察

目的:观察β胡萝卜素联合克林霉素治疗寻常痤疮的临床疗效和安全性。方法:将86例寻常痤疮患者随机均分为观察组和对照组。观察组患者给予β胡萝卜素胶囊30 mg,口服,每日2次+克林霉素胶囊300 mg,口服,每日2次,连用4周后,剂量改为β胡萝卜素胶囊15 mg,口服,每日1次+克林霉素胶囊150 mg,口服,每日1次;对照组患者给予异维A酸胶丸20 mg,口服,每日2次+克林霉素胶囊(用法用量同观察组),连用4周后,剂量改为异维A酸胶丸10 mg,口服,每日1次+克林霉素胶囊(用法用量同观察组减量后)。两组患者疗程均为3个月。观察两组患者临床疗效,治疗前后睾酮(T)、雌二醇(E2)、孕酮(P)、Toll样受体(TLR)、白介素(IL)-8、肿瘤坏死因子(TNF)-α水平及不良反应发生情况。结果:观察组患者总有效率显著高于对照组,两组比较差异有统计学意义(P<0.05)。治疗前两组患者T、E2、P、TLR、IL-8、TNF-α水平比较,差异均无统计学意义(P>0.05);治疗后两组患者T、P、TLR、IL-8、TNF-α水平均显著低于同组治疗前,且观察组低于对照组,而E2水平均显著高于同组治疗前,且观察组高于对照组,差异均有统计学意义(P<0.05)。观察组患者不良反应发生率显著低于对照组,两组比较差异有统计学意义(P<0.05)。结论:β胡萝卜素联合克林霉素治疗寻常痤疮较异维A酸联合克林霉素疗效更显著,安全性更好。     

Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study

In the treatment of mild to moderate acne vulgaris, the combination of an antibiotic and benzoyl peroxide provides enhanced efficacy over the individual agents, with the potential to decrease the emergence of resistant strains of P. acnes. To evaluate treatment regimens combining the daily use of a clindamycin/benzoyl peroxide gel, a tretinoin gel, and a clindamycin gel, the current randomized, evaluator-blind study was conducted. Results demonstrate that once-daily administration of clindamycin/benzoyl peroxide gel (combination formulation) was as effective as clindamycin/benzoyl peroxide gel + tretinoin gel + clindamycin gel. Both of these regimens provided greater efficacy than tretinoin + clindamycin. Treatment with clindamycin/benzoyl peroxide demonstrated a significant benefit over other treatments at Week 2, highlighting its rapid onset of action. All regimens were safe and generally well tolerated, with less severe peeling seen in patients who received clindamycin/benzoyl peroxide. In conclusion, the regimens that included clindamycin/benzoyl peroxide were more effective than tretinoin + clindamycin in the treatment of acne vulgaris, with no clinical advantage of adding tretinoin + clindamycin to once-daily clindamycin/benzoyl peroxide treatment.     

A multicenter efficacy and tolerability evaluation of benzoyl peroxide in a 10% urea vehicle for the treatment of acne vulgaris

BACKGROUND: Acne vulgaris is a common skin disease that affects 70 to 96% of individuals. Topical benzoyl peroxide has been used successfully for acne treatment; however, it may be accompanied by drying and or flaking skin. The addition of a 10% urea to the product excipient is theorized to moisturize the skin due to its humectant properties, aid in the efficacy of benzoyl peroxide due to its keratolytic properties, and effectively combat Propionibacterium acnes due to its antibacterial properties. OBJECTIVE: To assess the efficacy and tolerability of the treatment of acne vulgaris with multiple strengths of benzoyl peroxide in a 10% urea vehicle gel or cream and cleanser. Methods: A multicenter, non-randomized, open-label study in which 1,089 patients with acne vulgaris were enrolled at 133 participating physician office sites. Qualifying and consenting patients were prescribed either 4.5% or 8.5% benzoyl peroxide in a 10% urea vehicle cream or gel and cleanser. Additional medications were permitted during the study with the exception of those containing benzoyl peroxide. The physician assessed lesion counts, both inflammatory and non-inflammatory, at baseline and Week 4. Dryness and erythema were rated by the physician on a scale from 0 (none) to 8 (severe or deep) at baseline and Week 4. RESULTS: Nine hundred sixty-three patients completed the study. The following significant treatment arms were analyzed: patients treated with 4.5%/8.5% benzoyl peroxide in a 10% urea vehicle product only, patients treated with 4.5%/8.5% benzoyl peroxide in a 10% urea vehicle products along with oral doxycycline, and patients treated with 4.5%/8.5% benzoyl peroxide in a 10% urea vehicle products along with oral minocycline. A 44% (n=567) mean reduction in total lesion count was observed after 4 weeks of treatment with 4.5%/8.5% benzoyl peroxide in a 10% urea vehicle products only. Dual therapy using oral doxycycline (n=17) proved to be even more effective with a significant mean reduction in lesion count of 52% after only 4 weeks of treatment. Dual therapy using oral minocycline (n=21) yielded a significant mean reduction in lesion count of 34% after 14 weeks of treatment. The overall tolerability of the treatment illustrated the utility of urea as a moisturizing agent. CONCLUSION: Benzoyl peroxide in a 10% urea vehicle gel or cream and cleanser, used once daily for 4 weeks was found to be both effective and well tolerated for the treatment of symptoms related to acne vulgaris.     

消痤乳液对兔耳痤疮模型治疗作用的实验研究

目的：建立兔耳痤疮模型,观察消痤乳液对实验性痤疮的治疗作用.方法：将50%煤焦油溶液外涂于兔耳内侧导管开口处约2 cm×2 cm,连续14 d,制备痤疮模型 痤疮模型制备成功后将家兔分为6组,分别在兔耳患处涂高、冲、低剂量的消痤乳液,生理盐水,基质,克林霉素甲硝唑搽剂治疗,逐日观察痤疮模型的变化,于用药后7 d取患处皮肤活检并观察病理切片.结果：外涂煤焦油溶液14 d后,肉眼可见免耳出现不同程度的粉刺,病理切片显示模型组呈现与人类痤疮类似的病理改变 外用高、中剂量消痤乳液组治疗7 d,兔耳痤疮完全消退,皮肤接近正常对照组,克林霉素甲硝唑搽刺组兔耳痤疮大部分消退,皮肤仍有少量角化及粉刺颗粒,生理盐水及基质组痤疮无显著性变化.结论：消痤乳液对实验性兔耳痤疮模型有显著的治疗效果.     

Efficacy and safety of stabilised hydrogen peroxide cream (Crystacide) in mild-to-moderate acne vulgaris: a randomised,controlled trial versus benzoyl peroxide gel

BACKGROUND: Benzoyl peroxide (BP) is a first-line topical treatment in acne vulgaris (AV). However, its use can cause mild skin irritation and dryness. A new formulation of hydrogen peroxide stabilised (HPS) in monoglycerides cream (Crystacide 1%), indicated in the topical treatment of superficial skin infections, is now available as an alternative treatment. STUDY AIM: To evaluate efficacy and local tolerability of HPS in mild-to-moderate AV in comparison with BP gel. METHODS AND PATIENTS: In a randomised, prospective, investigator-masked parallel-group, 8-week trial, 60 patients (24 men, 36 women, mean age 25 +/- 6 years) with mild-to-moderate AV, affecting mainly the face, were enrolled in the study, after their informed consent. HPS or BP (PanOxyl gel 4%) was applied topically twice daily for 8 weeks. STUDY OUTCOMES: The study endpoints were: (1) Reduction in mean inflammatory (IL), noninflammatory (NIL) and total (TL) acneic lesions in comparison with baseline; (2) Local tolerability assessed evaluating erythema, dryness and burning sensation, using a 0-3 qualitative score (score 0 = poor tolerability; score 3 = very good tolerability). RESULTS: TL, NIL, and IL were assessed by an investigator unaware of treatment allocation at baseline, and week 8. The tolerability score (TS) was assessed at week 4 and 8. At baseline, the two groups were well matched for the main clinical and demographic characteristics. All patients concluded the trial. At week 0, in the HPS group TL, NIL and IL (mean +/- SD) were: 35 +/- 8, 20 +/- 6 and 16 +/- 7. At week 8, HPS reduced TL to 16 +/- 7; NIL to 9 +/- 3 and IL to 7 +/- 3 (p < 0.001). At baseline, TL, NIL and IL, in the BP group, were 32 +/- 9, 24 +/- 8 and 18 +/- 7, respectively. At week 8, BP reduced TL, NIL and IL to 14 +/- 9; 7 +/- 5 and 7 +/- 3 (p < 0.001). In comparison with baseline values, the percentage reductions of IL were 58% and 61% for HPS and BP,respectively (p = n.s.). At the end of the study the TS was 2.9 +/- 0.2 in HPS group and 2.4 +/- 0.8 in BP group (p < 0.025). Two patients in HPS group (6%) and seven patients (23%) in BP group suffered from mild-to-moderate local erythema. CONCLUSIONS: HPS has shown to be as effective as BP in reducing both inflammatory and noninflammatory AV lesions in patients with mild-to-moderate disease. In comparison with BP 4% gel, HPS cream shows a better local tolerability profile.     

异维A酸胶丸联合百癣夏塔热片治疗中重度寻常型痤疮临床疗效观察

目的：探讨异维A酸胶丸联合百癣夏塔热片治疗中重度寻常型痤疮的临床效果。方法：采用随机、平行、对照的临床试验,将78例受试对象随机分为对照组和治疗组;对照组30例常规使用异维A酸胶丸口服治疗,治疗组48例在上述治疗基础上联合百癣夏塔热片治疗,两组均外用克林霉素凝胶和0.025%迪维霜。疗程为6周,结束后观察疗效。结果：治疗组总有效率为89.58%,痊愈率为62.50%;对照组总有效率为66.67%,痊愈率为40.00%,两组疗效比较差异有统计学意义（P〈0.05）。结论：异维A酸胶丸联合百癣夏塔热片治疗中重度寻常型痤疮有较好的疗效,值得临床使用。     

他扎罗汀乳膏与阿达帕林凝胶随机对照治疗寻常型痤疮多中心临床试验

目的 评价国产0．1％他扎罗汀乳膏治疗面部轻中度寻常型痤疮的疗效及安全性。方法 用多中心、随机单盲对照试验方法，0．1％他扎罗汀乳膏或0．1％阿达帕林凝胶局部外用每日1次，疗程8周。在治疗前、治疗2，4和8周进行观察。入选病例142例，其中0．1％他扎罗汀乳膏组71例，完成8周观察64例。0．1％阿达帕林凝胶组71例，完成8周观察67例。结果他扎罗汀乳膏组有效率72．3％，阿达帕林凝胶组有效率62．7％。两组之间无显著统计学差异。两组的不良反应均表现为轻度到中度的局部刺激，发生率分别为28．70％和23．50％。结论 他扎罗汀乳膏治疗寻常型痤疮安全有效。     

Control of blood pressure in hypertensive patients with felodipine extended release or nifedipine retard.

1. This multicentre hospital study compared the antihypertensive efficacy and the tolerability of once daily felodipine extended release (ER) with twice daily nifedipine retard (R) in hypertensive patients inadequately controlled on metoprolol monotherapy. 2. One hundred patients, aged 20-70 years, whose seated diastolic blood pressure was 100-115 mmHg after 4 to 6 weeks of metoprolol (200 mg day-1) monotherapy, were randomised, double-blind, to receive felodipine ER 10 mg once daily or nifedipine R 20 mg twice daily for 8 weeks. The dosage of felodipine or nifedipine was doubled if seated diastolic blood pressure exceeded 95 mmHg, 2 or 4 weeks after randomisation. Metoprolol 200 mg once daily was taken throughout the trial. 3. Fifty-one patients received felodipine ER and 49 nifedipine R; 46 and 45 respectively completed the 8 week trial. About half of patients on each treatment needed the higher dose. The baseline characteristics of the felodipine and nifedipine groups were generally well balanced. 4. Seated diastolic blood pressure was reduced by 17 mmHg for felodipine (24 h post-dose) and by 9 mmHg for nifedipine (12 h post-dose), a difference between treatments of 8 mmHg (95% confidence interval 5 to 12 mmHg, P less than 0.0001). The attained blood pressures at the end of the study (felodipine 90 +/- 10, mmHg, mean +/- s.d.; nifedipine 95 +/- 10) were also significantly different (95% confidence interval for the 5 mmHg difference, -9 to -1 mmHg, P less than 0.02).(ABSTRACT TRUNCATED AT 250 WORDS)     

A multicenter clinical evaluation of the treatment of mild to moderate inflammatory acne vulgaris of the face with visible blue light in comparison to topical 1% clindamycin antibiotic solution

BACKGROUND: Blue light sources have been shown to be effective in the treatment of mild to moderate inflammatory acne vulgaris lesions. OBJECTIVE: We evaluated the safety and efficacy of a new blue light source in the treatment of mild to moderate inflammatory acne vulgaris in comparison to topical 1% clindamycin solution. RESULTS: Blue light therapy reduced inflammatory acne vulgaris lesions by an average of 34%, as compared to 14% for topical 1% clindamycin solution. CONCLUSIONS: The blue light source presented in this report is a safe and effective treatment option available to our patients with mild to moderate inflammatory acne lesions.     

Efficacy and tolerability of tiapamil in patients with mild to moderate essential hypertension

Although early experience with tiapamil, a new calcium antagonist structurally related to verapamil, showed good antihypertensive efficacy and minimal adverse effects, recent studies have shown conflicting results. This single-blind dose-titration study was designed to determine the therapeutic efficacy, duration of action, and safety profile of tiapamil in patients with essential hypertension. After a 2-week washout period, patients received placebo for 4 weeks. Patients with a sitting diastolic blood pressure (SDBP) of 95-114 mm Hg received tiapamil 300 mg twice daily with dose increments of 150 mg twice daily every 2 weeks to a maximum of 1,200 mg/day. Once blood pressure (BP) control was achieved or patients were receiving 600 mg twice daily, they were followed up for an additional 2 weeks. Twenty of the initial 31 patients completed the trial, and 17 patients were receiving the highest dose of tiapamil. Nine patients dropped out because of adverse effects. No significant decreases in BP and heart rate (HR) were either noted by the clinic or apparent by 24-h ambulatory BP readings. Random assays of drug supplies showed that patients received the required dosage. The incidence of adverse effects rose with increasing doses of tiapamil: 27.6% of patients at 300 mg twice daily, 48% at 450 mg twice daily, and 81.8% at 600 mg twice daily. Dizziness, headache, and palpitations were the most frequent adverse effects. These results show that tiapamil given at a daily dose of 600-1,200 mg exhibits very little effect in lowering BP in patients with mild to moderate essential hypertension. Moreover, the incidence of adverse effects is much higher than reported in earlier studies.     

红霉素醋酸锌凝胶和软膏治疗寻常型痤疮

目的：评价红霉素醋酸锌凝胶和软膏治疗寻常型痤疮的疗效和安全性。方法：采用随机、双盲、平行对照试验。以1%克林霉素磷酸酯凝胶为对照,设红霉素醋酸锌凝胶和红霉素醋酸锌软膏2个试验组,用药后6 wk评价疗效,并观察不良反应。结果：共入选60例病人。58例完成试验,对照组、软膏组和凝胶组各有19例,20例和19例。治疗6 wk后3组病人的黑头粉刺、白头粉刺、炎性丘疹和脓疱数较治疗前均有显著下降(P＜0.01),3组间变化无差异(P＞0.05)。对照组、软膏组和凝胶组有效率分别为58%,65%和63%,各组间疗效比较差异无显著意义(P＞0.05)。3组皮肤局部不良反应发生分别为3例,1例和1例,无全身不良反应发生。结论：红霉素醋酸锌凝胶和软膏是安全有效的治疗寻常型痤疮的外用药。     

雷贝拉唑与奥美拉唑三联疗法治疗老年性幽门螺杆菌阳性消化性溃疡疗效对比研究

目的探讨治疗幽门螺杆菌（Helicobacter pylori,HP）阳性的老年消化性溃疡的最佳用药方法。方法采用随机数字表法将HP阳性且年龄〉60岁的消化性溃疡患者100例分为对照组和观察组,各50例。对照组口服奥美拉唑20mg／次、阿莫西林1000mg／次及甲硝唑400mg／次,均每日2次,连用1周后单服奥美拉唑,20mg／次,每日1次,连服1周。观察组口服雷贝拉唑10mg／次、阿莫西林1000mg／次及甲硝唑400mg／次,均每日2次,连用1周后单服雷贝拉唑10mg／次,每El1次,连服1周。结果观察组愈合率为92．00％（46／50）,总有效率为98．00％（49／50）;对照组愈合率为78．00％（39／50）,总有效率为94．00％（47／50）;观察组愈合率明显高于对照组（X2=3．843,P〈0．05）,而总有效率差异无统计学意义（X2=1．042,P〉0．05）。观察组HP根除率为94．00％（47／50）,明显高于对照组的82．00％（41／50）,差异有统计学意义（X2=3．409,P〈0．05）。结论雷贝拉唑三联疗法较奥美拉唑三联疗法更能促进患者溃疡愈合、彻底根除幽门螺旋杆菌感染,是治疗消化性溃疡的理想用药方法。